Clients
Cuspis Capital I Ltd.
Cuspis Capital Ltd. (“Cuspis I”) was the first Capital Pool Company put together by the team at Cuspis Partners. Listed in March of 2019, the company raised $500,000 in its seed round, and $2,000,000 in its subsequent IPO. Cuspis I closed its Qualifying transaction with Graphene Manufacturing Group Ltd. in April of 2021.
Cuspis Capital II Ltd.
Cuspis Capital II Ltd. (“Cuspis II”), the second Capital Pool Company launched by the principals of Cuspis Partners, was listed in December 2020. This CPC raised $500,000 in its seed round, and $1,500,000 in its IPO. Cuspis II closed its Qualifying Transaction with IC Group Holdings Inc. in February, 2025.
Cuspis Capital II Ltd.
Cuspis Capital III Ltd. (“Cuspis III”), the third Capital Pool Company launched by the principals of Cuspis Partners, and the largest to date, was listed in February 2022. Cuspis III raised $1,000,000 in its seed round, and $5,000,000 in its IPO. Cuspis III closed its Qualifying Transaction with Cytophage Technologies Inc., in February, 2024.
Graphene Manufacturing Group Ltd.
Graphene Manufacturing Group Ltd. (“GMG”) worked with the team at Cuspis Partners to become a public company listed on the TSX-V exchange, through a transaction with our first Capital Pool Company, Cuspis Capital Ltd.
GMG is a clean-technology company that has developed and proven its own proprietary production process to manufacture graphene powder from readily available low-cost feedstock. This process produces high quality, low cost, scalable, ‘tuneable’ and contaminant-free graphene. The company’s focus has been on developing graphene enhanced applications for energy savings and energy storage solutions.
​
Cytophage Technologies Inc.
Cytophage and its founder have developed, over the past 15+ years, a suite of unique solutions to bacterial infection and disease with immediate applications in agriculture, aquaculture, and animal (livestock) and human health. They are moving rapidly to commercialize the products developed from their technology, with the first commercialization agreement signed in South Asia, and additional partnerships being pursued globally. The number of potential applications is vast, with the company focussed on a few markets (with global applications) in the short term. Production of their products is highly scalable, and margins are very attractive. While there are other companies pursuing similar approaches to treating bacteria, Cytophage's approach sets them apart in many important ways.
Field Safe Solutions
Field Safe Solutions is a cloud-based software as a service company based in Calgary, Alberta. The company’s safety applications connect workers and create smarter workflows that save time, money and lives.
Cuspis Partners is an investor in Fieldsafe Solutions and has provided capital markets advisory services to the company, as it grows.
IC Group Holdings Inc.
IC Group provides ad-tech, or marketing services technology, that is deeply embedded in their clients' operations, and typically under multi year agreements. The company has strong and longstanding relationships with large well-known brands (many Fortune 500 companies, for example). Most customers have been longstanding clients of the company, and include a broad range of recognizable names. IC Group's core business provides technology and services to run marketing, promotional, and customer loyalty programs for their clients around the globe, conducting campaigns for clients in more than 30 countries. With the recent acquisition of the Fannex business, several exciting growth opportunities are created. The Fannex technology platform makes it possible to aggregate and bring live event audiences (e.g. Sports, music, trade shows, etc.), to these same big brands, with a platform that ensures meaningful and valuable consumer engagement with these brand clients.
​
Diamond Therapeutics
Diamond Therapeutics is a team of world-class scientists and clinicians with expertise in developing treatments for disorders of the central nervous system. They develop safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines that have the potential to deliver a greater impact than current first-line treatments.​
​
Principals of Cuspis Partners are investors in Diamond, and Cuspis Partners' CFO, Grant McCutcheon, is presently acting as the CFO of Diamond as well.